Bleeding Events Up With Full-Dose Thromboprophylaxis in COVID-19
Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation
Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation
Major complications after cancer surgery doubled the odds of a late readmission for venous thromboembolism.
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Risk for thrombotic events reduced after 35 days of rivaroxaban compared with no extended thromboprophylaxis
In a landmark trial presented at AHA 2021, researchers aimed to understand the safety and efficacy of direct oral anticoagulants vs vitamin K antagonists in Black patients with non-valvular atrial fibrillation and venous thromboembolism.
Risk factors for postdischarge VTE include history of VTE, peak D-dimer >3 µg/mL, predischarge CRP >10 mg/dL
Receipt of any RBC transfusion was significantly associated with increased risk for venous thromboembolism.
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings
Long-term risks and consequences are considerable for patients receiving VKA, DOAC after first unprovoked VTE
Vaccination not associated with elevated risk for most of the adverse events examined; association found with increased risk for myocarditis, but risk higher in association with SARS-CoV-2 infection